实用医学杂志Issue(18)：2981-2984,4.DOI:10.3969/j.issn.1006-5725.2015.18.014
左氧氟沙星联合抗结核化疗方案治疗复治涂阳肺结核的临床研究
Clinical study on levofloxacin combined with anti tuberculosis chemotherapy in the treatment of retreated smear positive pulmonary tuberculosis
摘要
Abstract
Objective Investigate the clinical efficacy of treating retreated smear-positive tuberculosis patients with conventional anti-tuberculosis chemotherapy combined with levofloxacin. Methods Divide 60 retreated smear-positive tuberculosis patients registered in our hospital between October 2012 and October 2014 into two groups using random number table method: levofloxacin group and conventional treatment group. Each group contains 30 patients that were treated for 9 months , and the efficacy the both treatment methods were compared. Results The sputum conversion rate in the levofloxacin group is 93.33% and 96.67% after treating for 6 months and 9 months , respectively; which are substantial higher than that of the conventional treatment group with sputum conversion rate of 70% and 73.33% after 6 months and 9 months of treatment , respectively (P < 0.05). The absorption rate of the levofloxacin group is significantly higher than that of the conventional treatment group (P < 0.05). The cavity improvement rate of the levofloxacin group is 73.33%, which is significantly higher than that of the conventional treatment group (33.33%) (P < 0.05). The clinical efficacy of the LVFX group is substantially higher than the routine treatment group (P < 0.05). The overall effectiveness of LVFX group reached 100% , which is significantly higher than that of the conventional treatment group (86.67%) (P < 0.05). Conclusions Levofloxacin combined with conventional anti-tuberculosis chemotherapy can effectively improve the clinical efficacy in the treatment of tuberculosis.关键词
肺结核/复治涂阳/抗结核化疗方案/左氧氟沙星Key words
Pulmonary tuberculosis/Recurrent smear positive/Anti tuberculosis chemotherapy/Levofloxacin引用本文复制引用
梁冰,伍红,苏静怡,杜彩云,黄瑞霞..左氧氟沙星联合抗结核化疗方案治疗复治涂阳肺结核的临床研究[J].实用医学杂志,2015,(18):2981-2984,4.基金项目
广东省高科技发展专项（编号2012A030400058）；广州市胸科医院科研立项 （）
